Sign inJoin waitlistJoin the waitlist

Oana Danciu

Associate Director- Clinical Research, UICC Medical Director, Clinical Trials Office, UICC · University of Illinois College of Medicine at Chicago

Credentials: · · ·

History

University of Illinois College of Medicine at Chicago
Present

Hematology and Medical Oncology
University of Illinois College of Medicine at Chicago
2003–2006
Louis A Weiss Memorial Hospital
2000–2003
Carol Davila University
1996–2000

Research

Role of fascin in filopodial protrusion
The Journal of Cell Biology · 2006 · 405 citations
Association of Race/Ethnicity and the 21-Gene Recurrence Score With Breast Cancer-Specific Mortality Among US Women
JAMA Oncology · 2021 · 101 citations
Effect of Taxane Chemotherapy With or Without Indoximod in Metastatic Breast Cancer: A Randomized Clinical Trial
JAMA Oncology · 2021 · 50 citations

Kent Hoskins
8 papers
Judith Schlaeger
6 papers
Arkadiusz Dudek
4 papers
AZ
Ayesha Zaidi
3 papers · 2 as a resident
NV
Neeta Venepalli
3 papers
Grace Gao
2 papers
MN
Martin Nicholas
2 papers
MH
Matthias Holdhoff
2 papers
RE
Rajyasree Emmadi
2 papers
RP
Richard Peterson
2 papers
Rozina Chowdhery
2 papers
SF
Sarah Friedewald
2 papers

Clinical trials

BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder
Principal investigator · Not yet recruiting · Phase 1, Phase 2
University of Illinois at Chicago
2026–2031
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
Principal investigator · Recruiting · Phase 2
Oana Danciu
2022–2029
Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)
Principal investigator · Active not recruiting · Phase 1
University of Illinois at Chicago
2020–2027
Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2
Principal investigator · Terminated · Phase 1
Vanquish Oncology, Inc.
2017–2021